Cargando…
Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma
Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate p...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671052/ https://www.ncbi.nlm.nih.gov/pubmed/33235923 http://dx.doi.org/10.1080/23723556.2020.1834902 |
_version_ | 1783610854487359488 |
---|---|
author | Zhou, Weihua Wahl, Daniel R |
author_facet | Zhou, Weihua Wahl, Daniel R |
author_sort | Zhou, Weihua |
collection | PubMed |
description | Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate purine metabolism, its inhibition may overcome therapy resistance despite intratumoral genomic heterogeneity. |
format | Online Article Text |
id | pubmed-7671052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-76710522020-11-23 Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma Zhou, Weihua Wahl, Daniel R Mol Cell Oncol Commentary Profound intratumoral genomic heterogeneity has limited the ability of targeted therapies to overcome therapy resistance in glioblastoma. We have defined purine metabolism as a key mediator of DNA repair and radiation resistance in glioblastoma. Because many glioblastoma oncogenic drivers activate purine metabolism, its inhibition may overcome therapy resistance despite intratumoral genomic heterogeneity. Taylor & Francis 2020-10-27 /pmc/articles/PMC7671052/ /pubmed/33235923 http://dx.doi.org/10.1080/23723556.2020.1834902 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Commentary Zhou, Weihua Wahl, Daniel R Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma |
title | Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma |
title_full | Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma |
title_fullStr | Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma |
title_full_unstemmed | Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma |
title_short | Purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma |
title_sort | purine metabolism promotes radioresistance and is a therapeutic target in glioblastoma |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671052/ https://www.ncbi.nlm.nih.gov/pubmed/33235923 http://dx.doi.org/10.1080/23723556.2020.1834902 |
work_keys_str_mv | AT zhouweihua purinemetabolismpromotesradioresistanceandisatherapeutictargetinglioblastoma AT wahldanielr purinemetabolismpromotesradioresistanceandisatherapeutictargetinglioblastoma |